PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan II and acts as a non-selective melanocortin receptor agonist (MC1R, MC3R, MC4R). Unlike PDE5 inhibitors, PT-141 acts centrally via the hypothalamus rather than on the vascular system. It was the basis for FDA-approved Vyleesi (bremelanotide), making it one of the few research peptides with a direct FDA approval pathway. NewChem's PT-141 is supplied at ≥99% HPLC purity.
Add 2 mL bacteriostatic water for 5,000 mcg/mL.
Use our peptide reconstitution calculator →
Store lyophilised at −20 °C. Reconstituted: 4 °C, use within 28 days.
Every NewChem batch of PT-141 is independently tested prior to dispatch. Your COA documents HPLC purity (≥99%), identity confirmation via mass spectrometry, endotoxin screening, and a unique batch ID for full traceability. Sample COAs are available on request before purchase.
For a detailed step-by-step reconstitution guide for PT-141, including BAC water measurements, syringe unit conversions, and storage protocols, see our dedicated guide:
